NIH scientists reflect on gains in emerging infectious disease awareness, research and response

December 11, 2012

In a new essay, National Institute of Allergy and Infectious Diseases director Anthony S. Fauci, M.D., and David Morens, M.D., reflect on what has been learned about emerging infectious diseases (EIDs) in the two decades since a major report from the U.S. Institute of Medicine rekindled interest in this important topic.

Heightened awareness of EIDs is itself a countermeasure against disease, note the authors. The emergence of new diseases can now be monitored in real time online through Internet resources such as ProMED. In 2012 alone, such resources kept the scientific community and the public informed about the emergence in the Middle East of a novel disease-causing coronavirus; occurrences of illness at caused by a hantavirus; and the emergence in U.S. farm communities of a variant (H3N2v) that spread from swine to people. The authors point to advances that have improved the diagnosis, treatment and prevention of EIDs. Rapid sequencing of whole genomes, for example, allows for swift identification of new disease agents. The complex interactions between disease-causing microbes and human hosts are being revealed through approaches that describe entire biological systems holistically (). The data from such studies can be used to inform the development of drugs or vaccines. Recent appreciation of the sometimes beneficial role of communities of microorganisms dwelling in the gut, mouth, skin and other niches has reshaped the standard notion of infectious diseases as a simple contest between virulent invading pathogens and the .

The scientists emphasize the need for sustained commitment to developing countermeasures for specific diseases and to basic research that will lead to a greater understanding of infectious diseases and human susceptibility.

Explore further: NIAID scientists consider 200 years of infectious diseases

More information: DM Morens and AS Fauci. Emerging infectious diseases in 2012: 20 years after the Institute of Medicine report. mBio DOI: 10.1128/mBio.00494-12 (2012) (http://mbio.asm.org/content/3/6/e00494-12).

Related Stories

NIAID scientists consider 200 years of infectious diseases

February 2, 2012

Unpredictable, ever-changing and with potentially far-reaching effects on the fates of nations, infectious diseases are compelling actors in the drama of human history, note scientists from the National Institute of Allergy ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.